Benzinga | Jul 28, 2021 07:06AM EDT

MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study

Independent Data Monitoring Committee Recommends Continuation of the Study with

No Changes to Study Sample Size

No Safety Concerns Identified

Full Study Enrollment Expected by Year-End 2021; Data Readout Expected in the First Half of 2022